On the public citation graph

In Vitro Evaluation of Antimicrobial Peptide Tridecaptin M in Combination with Other Antibiotics against Multidrug Resistant Acinetobacter baumannii

https://doi.org/10.3390/molecules25143255

0 signed · 80 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.chembiol.2018.01.005openalex-snapshot

Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria

inferredcites →https://doi.org/10.1016/j.idc.2009.06.008openalex-snapshot

Pharmacokinetics and Pharmacodynamics of Antibacterial Agents

inferredcites →https://doi.org/10.1016/j.ijantimicag.2014.08.008openalex-snapshot

Unacylated tridecaptin A1 acts as an effective sensitiser of Gram-negative bacteria to other antibiotics

inferredcites →https://doi.org/10.1016/j.ijantimicag.2018.10.025openalex-snapshot

Repurposing azithromycin and rifampicin against Gram-negative pathogens by combination with peptide potentiators

inferredcites →https://doi.org/10.1016/j.ijantimicag.2019.02.016openalex-snapshot

Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation

inferredcites →https://doi.org/10.1016/j.jinf.2005.11.019openalex-snapshot

Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii

inferredcites →https://doi.org/10.1016/j.jiph.2018.07.006openalex-snapshot

In vitro evaluation of antimicrobial combinations against imipenem-resistant Acinetobacter baumannii of different MICs

inferredcites →https://doi.org/10.1016/s1473-3099(17)30753-3openalex-snapshot

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

inferredcites →https://doi.org/10.1021/acsinfecdis.0c00108openalex-snapshot

Effective Strategy Targeting Polymyxin-Resistant Gram-Negative Pathogens: Polymyxin B in Combination with the Selective Serotonin Reuptake Inhibitor Sertraline

inferredcites →https://doi.org/10.1021/acsinfecdis.9b00067openalex-snapshot

Small Molecule Potentiation of Gram-Positive Selective Antibiotics against Acinetobacter baumannii

inferredcites →https://doi.org/10.1038/nature10069openalex-snapshot

Metabolite-enabled eradication of bacterial persisters by aminoglycosides

inferredcites →https://doi.org/10.1038/nmicrobiol.2017.1openalex-snapshot

Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria

inferredcites →https://doi.org/10.1038/s41429-020-0291-8openalex-snapshot

Antibiotics in the clinical pipeline in October 2019

inferredcites →https://doi.org/10.1038/s41586-019-1791-1openalex-snapshot

A new antibiotic selectively kills Gram-negative pathogens

inferredcites →https://doi.org/10.1038/s41598-019-54716-8openalex-snapshot

Purification and biological activity of natural variants synthesized by tridecaptin M gene cluster and in vitro drug-kinetics of this antibiotic class

inferredcites →https://doi.org/10.1039/c5ob00780aopenalex-snapshot

Studies on tridecaptin B 1 , a lipopeptide with activity against multidrug resistant Gram-negative bacteria

inferredcites →https://doi.org/10.1073/pnas.1608623113openalex-snapshot

Antimicrobial lipopeptide tridecaptin A 1 selectively binds to Gram-negative lipid II

inferredcites →https://doi.org/10.1093/cid/cit253openalex-snapshot

Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

inferredcites →https://doi.org/10.1093/jac/44.5.641openalex-snapshot

In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa

inferredcites →https://doi.org/10.1093/jac/dkl274openalex-snapshot

Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections

inferredcites →https://doi.org/10.1093/jac/dkl303openalex-snapshot

Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam

inferredcites →https://doi.org/10.1093/jac/dkm509openalex-snapshot

Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections

inferredcites →https://doi.org/10.1093/jac/dkz034openalex-snapshot

Eradication of persister cells of Acinetobacter baumannii through combination of colistin and amikacin antibiotics

inferredcites →https://doi.org/10.1097/ccm.0000000000000181openalex-snapshot

The Deadly Impact of Extreme Drug Resistance in Acinetobacter baumannii*

inferredcites →https://doi.org/10.1111/mmi.13872openalex-snapshot

Expanding the paradigm for the outer membrane: Acinetobacter baumannii in the absence of endotoxin

inferredcites →https://doi.org/10.1128/aac.00200-17openalex-snapshot

Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741

inferredcites →https://doi.org/10.1128/aac.00296-11openalex-snapshot

Carbapenems: Past, Present, and Future

inferredcites →https://doi.org/10.1128/aac.00338-19openalex-snapshot

Tridecaptin M, a New Variant Discovered in Mud Bacterium, Shows Activity against Colistin- and Extremely Drug-Resistant Enterobacteriaceae

inferredcites →https://doi.org/10.1128/aac.00367-09openalex-snapshot

Efficacy of Rifampin and Its Combinations with Imipenem, Sulbactam, and Colistin in Experimental Models of Infection Caused by Imipenem-Resistant Acinetobacter baumannii

inferredcites →https://doi.org/10.1128/aac.00834-10openalex-snapshot

Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production

inferredcites →https://doi.org/10.1128/aac.00839-16openalex-snapshot

In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii

inferredcites →https://doi.org/10.1128/aac.01110-18openalex-snapshot

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

inferredcites →https://doi.org/10.1128/aac.02927-15openalex-snapshot

Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance

inferredcites →https://doi.org/10.1128/aac.04089-14openalex-snapshot

In Vitro Activities of Combinations of Rifampin with Other Antimicrobials against Multidrug-Resistant Acinetobacter baumannii

inferredcites →https://doi.org/10.1128/aac.26.4.546openalex-snapshot

Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa

inferredcites →https://doi.org/10.1128/cmr.00092-12openalex-snapshot

Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents

inferredcites →https://doi.org/10.1128/cmr.05041-11openalex-snapshot

Combination Therapy for Treatment of Infections with Gram-Negative Bacteria

inferredcites →https://doi.org/10.1128/mbio.01083-19openalex-snapshot

Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates

inferredcites →https://doi.org/10.1155/2015/679109openalex-snapshot

Antibacterial Mechanisms of Polymyxin and Bacterial Resistance

inferredcites →https://doi.org/10.1186/s12866-019-1416-8openalex-snapshot

Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa

inferredcites →https://doi.org/10.1186/s12941-019-0319-8openalex-snapshot

A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features

inferredcites →https://doi.org/10.1186/s12941-019-0339-4openalex-snapshot

Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients

inferredcites →https://doi.org/10.1186/s13054-017-1916-6openalex-snapshot

Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis

inferredcites →https://doi.org/10.1371/journal.pone.0151270openalex-snapshot

Antimicrobial Combinations against Pan-Resistant Acinetobacter baumannii Isolates with Different Resistance Mechanisms

inferredcites →https://doi.org/10.3109/07853890109002073openalex-snapshot

Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of Gram-negative bacteria

inferredcites →https://doi.org/10.3389/fcimb.2019.00193openalex-snapshot

Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria

inferredcites →https://doi.org/10.3389/fcimb.2019.00236openalex-snapshot

Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics

inferredcites →https://doi.org/10.3389/fmed.2019.00074openalex-snapshot

Treatment of Infections Due to MDR Gram-Negative Bacteria

inferredcites →https://doi.org/10.3389/fmicb.2018.02864openalex-snapshot

Purification, Characterization and in vitro Evaluation of Polymyxin A From Paenibacillus dendritiformis: An Underexplored Member of the Polymyxin Family

inferredcites →https://doi.org/10.3389/fmicb.2019.02153openalex-snapshot

Microbe-Derived Indole Metabolite Demonstrates Potent Multidrug Efflux Pump Inhibition in Staphylococcus aureus

inferredcites →https://doi.org/10.3390/antibiotics8020060openalex-snapshot

A Pilot Study of the Synergy between Two Antimicrobial Peptides and Two Common Antibiotics

inferredcites →https://doi.org/10.3390/microorganisms7100461openalex-snapshot

Global Burden of Colistin-Resistant Bacteria: Mobilized Colistin Resistance Genes Study (1980–2018)

inferredcites →https://doi.org/10.3390/molecules24050886openalex-snapshot

In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant Acinetobacter Baumannii

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4636654openalex-extracted

inferred← citeshttps://doi.org/10.1002/med.21879openalex-snapshot

Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections

inferred← citeshttps://doi.org/10.1007/978-981-16-3120-7_14openalex-snapshot

Recent Updates on Bacterial Secondary Metabolites to Overcome Antibiotic Resistance in Gram-Negative Superbugs: Encouragement or Discontinuation?

inferred← citeshttps://doi.org/10.1007/s00203-024-03998-2openalex-snapshot

Decoding antimicrobial resistance: unraveling molecular mechanisms and targeted strategies

inferred← citeshttps://doi.org/10.1007/s00203-024-04133-xopenalex-snapshot

Antimicrobial peptide-based strategies to overcome antimicrobial resistance

inferred← citeshttps://doi.org/10.1007/s00726-022-03187-9openalex-snapshot

A novel family of non-secreted tridecaptin lipopeptide produced by Paenibacillus elgii

inferred← citeshttps://doi.org/10.1007/s12088-025-01510-yopenalex-snapshot

Antimicrobial Peptides (AMPs) as Potential Antibiotics: Classification, Development and Future Prospects in Combating Multi-drug Resistant Pathogens

inferred← citeshttps://doi.org/10.1007/s12602-026-11093-9openalex-snapshot

Antimicrobial Peptides as Antibiotic Adjuvants: Overcoming Resistance through Multifaceted Mechanisms

inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.116097openalex-snapshot

Studies of antibacterial activity (in vitro and in vivo) and mode of action for des-acyl tridecaptins (DATs)

inferred← citeshttps://doi.org/10.1016/j.scitotenv.2025.179641openalex-snapshot

Harnessing advances in mechanisms, detection, and strategies to combat antimicrobial resistance

inferred← citeshttps://doi.org/10.1021/acschembio.4c00034openalex-snapshot

Discovery and Derivatization of Tridecaptin Antibiotics with Altered Host Specificity and Enhanced Bioactivity

inferred← citeshttps://doi.org/10.1021/acsinfecdis.4c00702openalex-snapshot

Advantages and Challenges of Using Antimicrobial Peptides in Synergism with Antibiotics for Treating Multidrug-Resistant Bacteria

inferred← citeshttps://doi.org/10.1038/s41467-025-56934-3openalex-snapshot

Exploring the principles behind antibiotics with limited resistance

inferred← citeshttps://doi.org/10.1039/d0md00413hopenalex-snapshot

The tridecaptins: non-ribosomal peptides that selectively target Gram-negative bacteria

inferred← citeshttps://doi.org/10.1039/d4md00745jopenalex-snapshot

Natural peptides and their synthetic congeners acting against Acinetobacter baumannii through the membrane and cell wall: latest progress

inferred← citeshttps://doi.org/10.1101/2022.04.07.487436openalex-snapshot

Antibiotic persistence of Brucella abortus in its protective intracellular niche

inferred← citeshttps://doi.org/10.1128/aac.01083-25openalex-snapshot

Preclinical evaluation of tridecaptin M: in vitro and in vivo efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics

inferred← citeshttps://doi.org/10.1371/journal.pntd.0010635openalex-snapshot

Antibiotic persistence of intracellular Brucella abortus

inferred← citeshttps://doi.org/10.2147/dddt.s405579openalex-snapshot

Antimicrobial Peptide Cec4 Eradicates Multidrug-Resistant Acinetobacter baumannii in vitro and in vivo

inferred← citeshttps://doi.org/10.3389/fbioe.2022.1051456openalex-snapshot

Advances and perspectives for antimicrobial peptide and combinatory therapies

inferred← citeshttps://doi.org/10.3389/fddsv.2024.1385460openalex-snapshot

Alternative therapeutics to control antimicrobial resistance: a general perspective

inferred← citeshttps://doi.org/10.3389/fphar.2026.1732644openalex-snapshot

Peptide-based antimicrobial effect against carbapenem-resistant Acinetobacter baumannii: preclinical drug assessment and translational potential

inferred← citeshttps://doi.org/10.3390/antibiotics10091095openalex-snapshot

Antimicrobial Peptides: A Potent Alternative to Antibiotics

inferred← citeshttps://doi.org/10.3390/antibiotics11020234openalex-snapshot

The Antimicrobial Peptide Esc(1-21) Synergizes with Colistin in Inhibiting the Growth and in Killing Multidrug Resistant Acinetobacter baumannii Strains

inferred← citeshttps://doi.org/10.3390/life13081651openalex-snapshot

Antimicrobial Peptides in Infectious Diseases and Beyond—A Narrative Review

inferred← citeshttps://doi.org/10.3390/pharmaceutics13060773openalex-snapshot

Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria

inferred← citeshttps://doi.org/10.5582/ddt.2024.01063openalex-snapshot

Novel and emerging therapeutics for antimicrobial resistance: A brief review

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.